Immix Biopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
The Company’s independent registered public accounting firm is Crowe LLP, Los Angeles, California; PCAOB ID#173. The information required by this Item is incorporated by reference from in the Company’s 2026 Proxy Statement to be filed with the SEC within 120 days after December 31, 2025, including, but not necessarily limited to, under the heading “Ratification of the Appointment of Our Independent Registered Public Accounting Firm for Fiscal Year Ending December 31, 2026 –Principal Accountant Fees and Services”.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.